ALNY vs ET Comparison

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Energy Transfer owns one of the largest portfolios of crude oil, natural gas, and natural gas liquid assets in the US, primarily in Texas and the US midcontinent region. Its pipeline network includes more than 12,000 miles of intrastate pipelines and 20,000 miles of interstate pipelines. It also owns gathering, processing, and storage facilities in the largest US oil and gas producing regions. Other businesses include a network of natrual gas liquids and refined products facilities, 18,000 miles of crude oil pipelines, and the Lake Charles gas liquefaction facility. Energy Transfer combined its publicly traded limited and general partnerships in October 2018.